2016

  • Arthesys is acquired by Q Holding Company, USA

2010 – 2013

Strategic investments focused on expansion of :

  • Capacity & logistics - Opening of India & China manufacturing facilities
  • Portfolio - Launch of Maya, 4th generation PTCA catheter
  • Know-how & expertise

2010

  • Aspiration catheter CE-mark: Pegase, 6F & 7F
  • Balloon platform compatibility demonstrated for biodegradable stents & Drug eluting balloons
  • Acquisition by Degania Silicone group

2009                     

  • CTO catheter (RX): Sirius
  • PTA range extension: Lynx (Long balloons up to 200mm)
  • Over the wire PTCA catheter CE-mark: Vega OTW

2008

  • 2nd generation PTA catheter CE-mark: Lynx

2006

  • 3rd generation PTCA catheter CE-mark: Vega

2005

  • Y-connector with hemostatic valve CE-mark
  • Cygnus Cobalt Chromium stent CE-mark

2003

  • 2nd generation of PTCA catheter CE-mark: Casiopea
  • PTA catheter CE-mark: Lyra
  • First coated stent crimping

2002

  • ActivGrip crimping process
  • 200 m² more dedicated to production

2001

  • Hydrophilic PTCA catheter CE-mark : “Alcyon + Hydro”
  • Over 700 m² dedicated to production

2000

  • Clean room extension
  • 275 m² added to production
  • 250 m² dedicated to R&D

1999

  • ISO 9001 & EN 46001 certification
  • 1st clean room installed
  • 1st generation PTCA catheter CE-mark: Alcyon

1998

  • ARTHESYS S.A. founded